NEC
12.1.2021 02:02:32 CET | Business Wire | Press release
NEC Corporation (NEC; TOKYO: 6701) today announced the development of “WISE VISION Endoscopy,” an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan today and is expected to soon be available in Europe. This software connects with existing endoscopy equipment as part of using AI to automatically mark potential lesions from images taken during endoscopic procedures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111006087/en/
Colorectal cancer is the most common cancer in Japan (*1), and the second most common in Europe (*2). Colorectal cancer originates from precancerous lesions (colorectal neoplastic polyps) and it is possible to suppress the progression to cancer by detecting and removing lesions at the polyp stage during endoscopy procedures. However, polyps need to be found with the eye of an endoscopist, and are often difficult to detect because of their size and shape, causing approximately 24% (*3) to be missed, thereby delaying detection.
NEC has been working with the National Cancer Center Japan since 2016 to contribute to resolving this issue. NEC has now developed software that can automatically mark potential lesions based on the use of AI to learn from endoscopic images of more than 10,000 lesions, as well as learning from the observations of expert physicians (*4). This software was developed by applying NEC’s AI technologies, “NEC the WISE,” and its face recognition technology, which is highly evaluated by the National Institute of Standards and Technology (*5) in the United States.
Software features include the following:
1. Compatibility with the endoscopy systems of three leading companies and usability in any examination room
This software can be connected to endoscopes from three leading endoscope manufacturers (*6). By simply connecting an existing endoscope to a monitor and terminal equipped with the software, users can start using it immediately. Moreover, since it is compatible with various endoscopes and easy to prepare, systems can be transferred within different rooms and used efficiently wherever there is an examination.
(Shown in Graphic 1)
2. High visibility and flexible interface
The system marks the lesion candidates with a notification sound and marking. Notification sounds, volume, and marker colors can be customized at any time to the user's preference. The system can be operated intuitively with a high-visibility user interface, allowing users to smoothly proceed with examinations.
Going forward, as a company that creates social value, NEC aims to promote a healthy, and sustainable society, where individuals can thrive from the utilization of advanced IT technologies.
(Shown in Graphic 2)
(*1) According to statistics from the National Cancer Research Center Japan (Japanese text only)
https://ganjoho.jp/reg_stat/statistics/stat/summary.html
(*2) According to United European Gastroenterology
https://ueg.eu/p/78#
(*3) Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology. 1997;112(1):24-28
(*4) Yamada M, Saito Y, Imaoka H, et al. Development of a real-time endoscopic image diagnosis support system using deep learning technology in colonoscopy. Sci Rep. 2019;9:14465
(*5) NEC Face Recognition Technology Ranks First in NIST Accuracy Testing
https://www.nec.com/en/press/201910/global_20191003_01.html
(*6) Connectivity and operations have been confirmed with the following endoscopes
- Olympus EVIS LUCERA ELITE Video System Center CV-290
- FUJIFILM ELUXEO video processor VP-7000
- PENTAX Medical OPTIVISTA EPK-i7010 video processor
Product name: WISE VISION Endoscopy
***
About NEC Corporation
For more information, visit NEC at www.nec.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111006087/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 20269.2.2026 13:00:00 CET | Press release
TarSeer™ BRETSA™ Target Engagement System enables studies for difficult proteins early in drug discovery Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins. The TarSeer™ BRETSA™ Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. It gives drug discovery researchers early, target-specific cellular insights by validating weak or early chemical matter and expanding the targets accessible in live-cell drug discovery workflows. The technology will be debuted at the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, February 7-11, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206015371/
Eurofins Viracor BioPharma Expands Bioanalytical Capabilities9.2.2026 13:00:00 CET | Press release
Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor BioPharma’s purpose‑built, eleven‑acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories’ strengths, Eurofins V
HKTDC to Host World’s Largest One-Stop Jewellery Marketplace9.2.2026 11:37:00 CET | Press release
New Hard Pure Gold Pavilion showcases breakthrough gold technologies Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one‑stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld‑Expo, featuring a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre, showcasing finished jewellery pieces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260207153040/en/ Hong Kong International Jewellery Show and Hong Kong International Diamond, Gem & Pearl Show Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with nearly 70% coming
FlexTrade Integrates CME Group’s FX Spot+ and EBS Market Offerings for Enhanced FX Trading9.2.2026 11:30:00 CET | Press release
The initiative will see FlexTrade FX clients seamlessly access CME Group’s primary FX markets within FlexFX. FlexTrade Systems(@FlexTrade), a global leader in multi-asset execution and order management systems, today announced an integration with CME Group’s EBS Market central limit order book (CLOB) and its FX Spot+ platform.The move is designed to diversify and deepen the sources of actionable liquidity available to FlexTrade’s FlexFX users through an integration into CME Group's substantial liquidity pools for spots via FX Spot+. Providing firm, anonymous liquidity and no last-look pricing, EBS Market is a venue for both large market participants in search of FX liquidity in an all-to-all CLOB, and for market-making banks hedging FX risk. FX Spot+ further enhances spot liquidity with Futures liquidity from CME Group. This partnership is integral in helping firms further expand FX liquidity and take advantage of global opportunity. Mutual clients of FlexTrade and CME Group can integr
Clearwater Analytics Debuts Transparent Risk Platform for Power and Gas Markets at E-world 20269.2.2026 09:00:00 CET | Press release
CWAN Power and Gas breaks industry reliance on black-box systems as energy transition drives trading opportunity At E-world Energy & Water 2026, Clearwater Analytics (NYSE: CWAN) will debut CWAN Power and Gas, new risk management capabilities within Beacon by CWAN designed to end the industry’s reliance on black-box systems. With transparent methodologies and source-code visibility, the platform lets trading teams validate and customize calculations for complex power and gas instruments in real time. Visit Booth #5A118 in Hall 5 for live demonstrations. Renewables growth, liquefied natural gas flows, and shifting macroeconomic conditions are reshaping power markets and increasing both volatility and opportunity. Yet many trading firms remain constrained by legacy risk platforms that limit model visibility, customization, and speed-to-market. CWAN Power and Gas removes those constraints by making every calculation transparent, configurable, and auditable in real time—supporting complex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
